Medical Device News Magazine

Gynesonics Announces First Office-Based Sonata Treatment Procedure in the State of Texas

Dr. John Thoppil, Current President of the Texas Association of Obstetricians and Gynecologists (TAOG), Performs Sonata Procedure in Austin

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Dr. John Thoppil is the first physician in the state of Texas to offer its Sonata® Treatment to women with symptomatic uterine fibroids as an office-based procedure at his River Place OB/GYN facility in Austin.

“I am excited to offer this transcervical option for fibroid treatment in an office setting.  Sonata is brilliant in concept; it reduces symptoms without any incisions at all,” said John Thoppil, MD, FACOG and President of TAOG.  “We are honored to be the first medical group to offer Sonata in-office, in the state of Texas.  In addition to the office, we will be offering the procedure in the traditional outpatient surgical center setting.  The ability to utilize multiple sites of service, with no incisions and a rapid recovery, is one of the most important recent treatment advances for women with symptomatic fibroids and their physicians, not only in Texas, but across the globe.”

The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.  The Sonata Treatment is a breakthrough alternative to hysterectomy and myomectomy, and can treat a wider range of fibroid types, sizes, and locations than hysteroscopic myomectomy.  Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained.  (FDA cleared.)

“We are incredibly fortunate to have advocates like Dr. Thoppil, who are able to quickly utilize the advantages unique to the Sonata Transcervical Fibroid Ablation (TFA) Procedure,” said Chris Owens, President and CEO of Gynesonics.  “The recent guidelines released by the American College of Obstetricians and Gynecologists (ACOG) recognized TFA as an important fibroid treatment that can be offered to women.  Sonata is the only fibroid ablation system that does not require incisions or abdominal surgery.  Sonata has been uniquely designed to help patients gain access to care through multiple sites of service, supporting rapid adoption around the globe.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”